menu search

TALS / Talaris Therapeutics to Participate at Two Upcoming Investor Conferences

Talaris Therapeutics to Participate at Two Upcoming Investor Conferences
BOSTON and LOUISVILLE, Ky., March 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune disorders, today announced that members of its senior management team will participate at the following investor conferences: Read More
Posted: Mar 22 2022, 16:01
Author Name: GlobeNewsWire
Views: 112554

TALS News  

Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk

By Seeking Alpha
August 29, 2022

Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk

Shares of cell therapy concern Talaris Therapeutics crashed nearly 70% after GvHD outcomes in three Phase 3 trial kidney transplant patients were reve more_horizontal

Talaris Therapeutics to Participate at Two Upcoming Investor Conferences

By GlobeNewsWire
March 22, 2022

Talaris Therapeutics to Participate at Two Upcoming Investor Conferences

BOSTON and LOUISVILLE, Ky., March 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company d more_horizontal


Search within

Pages Search Results: